Last quarter, revenue soared 151% to $29 million, with projections pegging it at $167 million for 2025. And there’s a $1.2 billion backlog waiting in the wings. In this cutthroat game, such figures are as intoxicating as a moonlit speakeasy.
July 2025 rolled in like a gull with a grudge, leaving crypto platforms gasping in its wake. The numbers don’t lie: $142 million vanished like smoke, and CoinDCX, GMX, and BigONE were the main courses at the hackers’ feast. CoinDCX? They lost enough to buy every man, woman, and child in their city a year’s … Read more
Merck, a name spoken with a respect bordering on reverence in the pharmaceutical corridors, has, for fifteen years without interruption, witnessed the quiet blooming of its dividend, a dependable rhythm in a world increasingly given to chaotic fluctuations. Yet, the past is not without its shadows. Before this current streak, an unsettling pause, a stillness that felt like a held breath, preceded it, even as its rival, Pfizer, dared to sever its own promise. To increase perpetually is a dream, of course, but to avoid the blade – that is a victory worthy of contemplation.
Before us stands Target (TGT), a titan of retail, now humbled by a 61% fall from its 2021 peak. Theft and tepid same-store sales have marred its once-proud facade. Yet, beneath the surface, resilience persists. Last year, it clawed $4 billion in net profit from $105 billion in revenue.
Now, if you’ve got exactly $100 to invest and a death wish for your portfolio, here are two industrial stocks that might make you feel like a genius… or a fool who forgot to check the fine print.
The current disquiet centers, predictably, upon the flow of coin. The second quarter’s free cash flow, a sum of $692 million, appears to have unsettled investors. A decline of forty-nine percent year on year. To the casual observer, a darkening of the ledger. Yet, such metrics are but shadows cast by the sun of expectation.
The latest quarterly figures did more than whisper—they shouted, “Yes, we are still relevant.” It’s tempting for investors to interpret this as a golden ticket, an unassailable lead in the streaming barnyard that’s expanding faster than the average American’s interest in pizza. But behind the scenes, there’s an undercurrent that’s quietly shaping the future of streaming—artificial intelligence, or as I like to call it, the digital crystal ball that everyone pretends to understand.
But not every tech stock is a flash in the pan. A few AI players are built on solid ground, with enough moat and margins to catch the eye of even the most cautious investor. I’ve been tracking them – and if you’re looking to add some AI exposure without the wild swings, these are the names you want on your radar.
Below are five companies that combine economic moats with disciplined capital allocation—characteristics that have historically rewarded long-term shareholders.
What is a corporation, if not a living entity, its soul fractured by the ghosts of its deeds? Johnson & Johnson, for all its gilded façade, is a creature of contradictions—a paragon of innovation shackled by the chains of its past. The question that gnaws at the marrow of its existence is not merely financial, but existential: Can a company, born of human frailty, transcend the sins of its progenitors?